Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have no problem with traders. I also do not have a problem with news being releases via Tweets or other social media. I agree that an investor has do adapt. My problem is the irresponsible way that social media is used. One line blurbs, with no explaination, that create unjustified and uncontrollable reactions with no responsibilty or consequences for the people who put them out, (I am not just talking about in the stock market), that is what I have a problem with.
The point was not that they Tweeted, it was the fact that it said nothing. What was the reason for not releasing the actual newsworthy info? If there was a reason they should have said nothing at all until they could release it.
Whoever released it caused serious consequences to a lot of people.
Fake news would be if they stated something that was not true.
Nothing was stated yet, once again speculators took it and ran with it, creating the frenzy. I have to say I do not agree with/like them teasing a news release. It is unfair to investors who are trying to find an entry point based on DD and company fundamentals. (people who will be around for the lng term). It works well for speculative day traders (those who could care less about the company) who jump in and out for a quick buck.
Release the news or stay quiet. That way the investor and the trader have the same chance of making their move.
What we witnessed yesterday had NOTHING to do with investing.
As I said in a previous post, I would not be surprised to see a new round of lawsuits based on that Twitter statement.
As for the news when it comes out, it may be "exciting" for some but yet not all that great when it comes down to the earnings/financial situation.
Profits are good, better missing a bit of the run than sticking around for the return to earth.
Still on the sidelines, if it turns out to be real news there will be time to ride it up.
My only guess, AND THIS IS A GUESS, could it have something to do with the sales and production JV in China, that was mentioned in the conference call?
Still out...if you look back at today's posts, I just finished posting and the thing took off. Made me look like d#*k...lol
I agree, I believe that was already out there.
Accuracy? It didn't say anything!
"We have exciting news on it's way! Stay tuned to find out the latest at Ekso Bionics"...#Stroke
This is even more vague than the Ford article.
Management could well have opened themselves up for a new round of lawsuits if this heads back south just as quickly, if the "news" turns out to be nothing important and someone there profits from the move.
"Exciting" could mean anything...It could be directed to patients and not have a big impact on revenue....on the other hand, who knows?
Looks like a Tweet on their website is what caused that...Very vague, be careful here.
Just as I say that there is a huge upward spike. What is that about?
Porsche...Looking like they want to test the 1.40 support level again. With charts breaking down I'm thinking it won't hold there and after that 1.30 is not really support. I still have not jumped back in, still watching closely though, for news.
Also, I did read your post before it got deleted. I guess technically off topic, even though you were complimenting the posters here and IHUB in general.
I just want to say that I appreciate all the information that you and all the others who post here bring to the discussion. You all make this board, IMO, the best board, anywhere. This is a place where people can come to do what message boards are designed for. DISCUSS the company, the industry and the stock intellegently. Everyone contributes with links or references to back up what they post and are grateful to have others contribute their knowledge or insight even if it means we are corrected every once in a while.
When I read posts here I look through them to see if I can follow any hints or clues in order to find follow up or new info that I would not have known to look for without the original post. Many of your posts have been the starting point for me to follow all the branches and see what other info they may lead to.
I think others here do that as well and that is what makes this a great board and great resource.
THANK YOU TO EVERYONE!
Your posting information from here on the ST board allows for the more knowledgable and information oriented people to add their comments and follow up info on that site. I just follow the replies to your post in order to see if anyone has uncovered some info that we here have missed or can benefit from reading without having all the nonsense posters coming here.
I don't post on sites like that because; frankly, I get very aggrevated and annoyed at people who post nonsense, factless BS in an attempt to make themselves appear intelligent and take no responsibility for the times when they are completely wrong. Also can't stand hearing all the conspiracy theories that are directed toward the company when things aren't going the way people wish they would.
I look for forward to your continued posts here and any new info you may find.
Dec 2017 article...
https://www.xconomy.com/national/2017/12/04/rewalk-ekso-race-to-sell-exoskeletons-in-tough-rehab-market/
Another point not mention in this article but previously mentioned by Bobby Marinov is the need for and progress being made by different groups to standardize both the language/terminology used and the testing and requirements of the devices.
Many of the differences in companies are beginning to narrow for the betterment of all.(my opinion)
I previously posted this Article from April 2017...I think it helps to compare where the 2 companies were then and where they are now. What progress has be made and have any of the hurdles been removed or breached.
Making progress on the insurance issues.
Still burning cash.
Still just above NASDAQ requirements.
Expanding on your point about starter position in RWLK...I don't see much down side at their current PPS, I think (would have to look into further) the past issues of the reasons for the short attack some time ago have faded. Also, they are bound to have PPS spikes along the way that you can take advantage of. Those spikes would most likely occur while you wait for EKSO to spike. Then, if news comes out that benefits the entire industry, such as insurance acceptance, you can ride both (all 3, with BNKL) higher.
Don't mind at all. Just noticed that some of the info looked familiar. From the short time that I have been checking out the ST posts, yours are pretty much the only ones with real usable info. Many of the others are non-sense babble. That is one thing this board has next to none of.
Good to have others mining for DD.
I think taking a starter position in the other companies is a wise move, for the reason you stated. I believe there will be several winners.
Insurance coverage is the key. I believe they are slowly coming around.
Also agree with chart assessment. With no catalyst (news) I don't see how it breaks to the upside. I feel we will at least test the 1.30 point at some point. May be a while. Still treading water.
This is a link that rkt posted...Older video, (2014) Mr. Harding is in the video...but still interesting info to help put all the bits and pieces of the info puzzle together
Found the same video in your posted linked on a post on Stock Twits...it says the video is from 2015
There is someone there who posts as rkt...I assume he checks this board out because several of his posts have been mentioned points that have appeared here just before he posted them.
https://techcrunch.com/2017/07/18/rewalk-robotics-shows-off-a-soft-exosuit-designed-to-bring-mobility-to-stroke-patients/
There are 2 video clips in this article. The first shows cables and this statement..."Based on designs created by Harvard Wyss Institute as part of a DARPA project.
The second shows a soft exosuit ...I believe using cable system (covered by the material around the ankle)
https://wyss.harvard.edu/wyss-institute-collaborates-with-rewalk-robotics-to-develop-wearable-exosuits-for-patients-with-limited-mobility/
Last paragraph...
Harvard’s Office of Technology Development worked with the Wyss Institute to structure this collaboration with ReWalk, which includes a license for intellectual property and funding for the continued development at the Institute, towards bringing this new wearable therapeutic device into the marketplace. Additional funding for the Wyss Institute’s exosuit came from the National Science Foundation, the Harvard University Star Family Challenge, and the Defense Advanced Research Projects Agency’s Warrior Web program, which seeks to develop technologies to mitigate musculoskeletal injuries among military Service members while improving performance.
If you have not seen the EKSO GT in use, here is a video of it being used at Good Shepherd Rehabilitation Network which is just 4.5 miles from my home. It is an older video that I had posted a while back but thought that new people to the board would be interested in seeing it. I spoke to Sue a few years back. She was a great help in my learning about the GT.
Some of the countries in which we operate and seek to expand are in emerging markets where legal systems may be less developed or familiar to us. Other jurisdictions in which we conduct business may establish legal and regulatory regimes that differ materially from United States laws and regulations. Compliance with diverse legal requirements is costly and time-consuming and requires significant resources. Violations of one or more of these regulations in the conduct of our business could result in significant fines or monetary damages, criminal sanctions against us or our officers, prohibitions on doing business, unfavorable publicity and other reputational damage, restrictions on our ability to process information and allegations by our clients that we have not performed our contractual obligations.
This portion from the 10-k addresses the point I brought up concerning IP protection...
As we look to expand into China, we may be exposed to the additional risks of doing business in China. Our success in the Chinese markets may be adversely affected by China’s continuously evolving laws and regulations, including those relating to taxation, import and export tariffs, currency controls, anti-corruption, environmental regulations, indigenous innovation, and intellectual property rights and enforcement of those rights. Enforcement of existing laws or agreements may be inconsistent. In addition, changes in the political environment, governmental policies or United States-China relations could result in revisions to laws or regulations or their interpretation and enforcement, exposure of our proprietary intellectual property, increased taxation, restrictions on imports, import duties or currency revaluations, which could have an adverse effect on our business plans and operating results.
If we are unable to meet and overcome these challenges, then our international operations may not be successful, which could adversely affect our net sales, results of operations and financial condition and limit our growth.
Home Mobility
The dynamics and product requirements of the home mobility market are different from those of the clinic. While we believe the home mobility market opportunity is sizable, it will only be served once next generation technology is brought to market that is cost effective for individuals because reimbursement is available and has a level of functionality that enables independent mobilization. Home mobility exoskeletons should be fitted to a specific patient and designed for all-day use. In addition, we believe they must be easily transportable, and have improved dynamic stability, user interfaces, and terrain navigation to allow the home users to confidently walk through their daily life with little or no assistance. As we continue to develop our commercial experience with a medical exoskeleton in the rehabilitation setting, coupled with recent research and development advancements in exoskeleton and related technologies, we are now investing resources to design such a commercial product and to develop our go-to-market approach for mass adoption of home mobility devices. We are also collaborating with world-class academic and commercial institutions to refine our technology and to apply the latest technological breakthroughs to the advancement of human ambulation.
In addition to implementing the technological changes necessary in an exoskeleton designed for the home mobility market, we are in parallel working with payers and ensuring our (and where possible, our partners’) trials are and will be generating clinical and economic evidence on the benefits of exoskeletons for home mobility use. Lastly, the go-to-market strategy will likely be quite different than our current sales and marketing approach for the rehabilitation markets. Critical to our success will be implementing such a strategy, possibly with partner(s), which is sustainable to address the potential size of the market.
These lines comes from the 10-K filing...referring to the Ekso-GT
Beginning late 2017, we expanded our focus to include Asia-Pacific and initiated an effort to seek a strategic partnership for the sales and manufacture of the Company’s products in China.
Manufacturing and Supply Chain
We produce the Ekso GT at our facilities in Richmond, California. We currently run one line for one shift per day and believe we have the capacity to eventually run up to four lines for two shifts per day should we deem it appropriate. The Ekso GT uses over 700 purchased parts, which we source globally from over 70 suppliers. Whenever possible, we seek to secure dual source suppliers for our components.
I think part of the testing is determining how long that savings rate decreases over the life of the device. Specs and expectations are one thing but real life performance may be something different. I'm sure there are many other factors they are looking at.
Looks like we are back in the 1.40-1.60 range again, with 1.40, 1.50 and 1.60 being where the battles always take place. Currently knocking at 1.50 and trying to push it lower while others are trying to hold above.
I am still holding my money, I didn't feel there would be anything different in the earning that wasn't in the prelim report. Now the question is, with that news out of the way, what catalyst is there to cause a jump in PPS? We are back to the same old situation, with no news do we move sideways or drift lower?
There are other companies manufacturing a competitive product. Yes, the technology is proving to be useful and beneficial but that does not mean EKSO will be the supplier.
See post #5052...I believe it mentions that testing is still ongoing with Ford, but it also shows how another company can come in with it's version of the product as did Levitate Technologies, with their AIFRAME device at BMW.
It becomes more of a concern when it seems that they are banking on China/Asia being a large part of their future. Without that market I can't see how they compete.
One concern that I am beginning to think about more often is the recent increase in anti- China policies and concerns about IP theft/purchasing. How does a company that has associations (if they even still do) with DARPA balance National Security and business dealings with China. I would assume that some of the same patents and technology cross over between the medical/commercial/industrial applications and the military apps.
Have to laugh at some of the comments on other boards. I don't understand how they are surprised by the earnings numbers either way, they are the same as the preliminary release.
Just finished listening to the conference call...I have to say that I was not impressed. I saw nothing that would push the PPS any time soon. Even when asked about the Ford article at the end, the response was hedged and he said he was "cautiously optimistic".
There was one mention of Joint Venture in China, but it seem to me, like that is in negotiation/development stages, nothing immediate.
Below are the points I found to be of interest, they are just a portion of the 8-k filed...you can read the entire 8-k at the link provided in the news alert
(h) Mr. Looby has agreed not to sell or otherwise dispose any of his Common Stock for a period of 90 days after the date of his resignation,
Mr. Looby and the Company each have agreed not to disparage the other, and each have agreed to a release of claims related to the relationship between Mr. Looby and the Company and its affiliates, and his separation.
Mr. Peurach is a director of the Company, and, prior to his appointment as the Company’s President and Chief Executive Officer, served as the Chairman of the Compensation Committee of the Board and as a member of the Nominating and Governance Committee and the Audit Committee of the Board. Mr. Peurach served on the board of directors of Ekso Bionics, Inc., which merged with a wholly-owned subsidiary of the Company in January 2014 and continued as the surviving entity in the merger, from July 2011 until the merger, and has served on the board of directors of the Company since the merger.
On March 9, 2018, Mr. Howard Palefsky and Ms. Amy Wendell, each a member of the Board, notified the Company of their decision to resign from the Board and from all committees of the Board, effective immediately. The resignations of Mr. Palefsky and Ms. Wendell were due to differences between them and a majority of the Board in areas of corporate strategy, but there were no disagreements between them and the Company relating to the Company’s operations, policies or practices.
On March 11, 2018, Charles Li, Ph.D. was appointed to the Board. Dr. Li will serve as a director of the Company until the next annual meeting of stockholders of the Company and until his successor is elected and qualified. Dr. Li has also been appointed as a member of the Audit Committee of the Board.
A few more details...(entire article at this link)...
https://www.nasdaq.com/press-release/ekso-bionics-announces-executive-leadership-changes-jack-peurach-cofounder-of-ekso-bionics-longtim-20180312-00463
"The Board of Directors thanks Tom, Howard and Amy for their many contributions to Ekso's growth. Tom's leadership has been instrumental in strengthening and professionalizing our global commercial and marketing operations," said Steven Sherman, Chairman of the Board of Ekso Bionics. "As one of Ekso Bionics' founders, Jack has been a steadfast catalyst for driving Ekso Bionics' evolution since inception. His extensive commercial experience coupled with his keen understanding of our business will enhance our ability to realize Ekso's full potential as the innovation leader in the field of human augmentation. I am confident that Jack is the right person to guide Ekso's next chapter of growth. We also welcome Charles to the Board of Directors as we know his expertise will prove immediately beneficial."
In connection with his appointment as the President and Chief Executive Officer of Ekso, Mr. Peurach resigned his positions as the Chair and a member of the Compensation Committee of the Board and as a member of the Audit Committee of the Board. Dr. Li has filled Mr. Peurach's position as a member of the Audit Committee of the Board, and Mr. Sherman was appointed as the Chair of the Compensation Committee of the Board in place of Mr. Peurach. Mr. Sherman was also appointed as the Chair of the Nominating and Governance Committee of the Board to replace Mr. Palefsky.